hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06305273, orgStudyIdInfo id: 23-0150-A, briefTitle: Effectiveness of Two Different Body Positions During Facemask Ventilation in Obese Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-25, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Mount Sinai Hospital, Canada, class: OTHER, descriptionModule briefSummary: It is important to provide enough oxygen to the patients who are asleep during surgery. One way to do this is by using a mask placed over the face to help them breathe. When it becomes difficult getting enough oxygen into the patient's body using the mask, it's called difficult mask ventilation. There can be different reasons for this, and having a higher BMI is one of them. Body physique is assessed by Body Mass Index (BMI). This calculation gives an indication of a person's weight relative to their height.There is some evidence in the research literature to suggest that when the patient is positioned in a way that helps their airway, like using a device to lift their head and torso 25 degrees, it might help the process of getting enough oxygen work better. The study aims to determine if patients with high BMI can breathe better using a face mask while they are in a head elevated position compared to lying flat on their back., conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, interventionModelDescription: This study is a prospective randomized cross-over trial to be conducted at Mount Sinai Hospital (Toronto, Ontario, Canada)., primaryPurpose: PREVENTION, maskingInfo masking: NONE, enrollmentInfo count: 38, type: ESTIMATED, armsInterventionsModule interventions name: Head position for face mask ventilation during induction supine, interventions name: Head position for face mask ventilation during induction head elevated, outcomesModule primaryOutcomes measure: Average tidal volume, secondaryOutcomes measure: Predictors for difficult mask ventilation like BMI, secondaryOutcomes measure: Predictors for difficult mask ventilation like presence of beard, secondaryOutcomes measure: Predictors for difficult mask ventilation like Mallampati classification III or IV, secondaryOutcomes measure: Predictors for difficult mask ventilation like age of 57 yo or older., secondaryOutcomes measure: Predictors for difficult mask ventilation like severely limited mandibular protrusion, secondaryOutcomes measure: Predictors for difficult mask ventilation like history of snoring., secondaryOutcomes measure: Oropharyngeal airway, secondaryOutcomes measure: Insufficient mask ventilation, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06305260, orgStudyIdInfo id: STUDY00000324, briefTitle: LOTUS Trial: Lumbar Ultrasound in Obstetric Patients With BMI > 40, acronym: LOTUS, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2023-11-01, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: MetroHealth Medical Center, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare traditional palpation to pre-procedural lumbar ultrasound prior to epidural placement in obese (BMI \>40) obstetric patient population. The main questions it aims to answer are:* Is a pre-procedural lumbar ultrasound superior to traditional palpation in terms of total number of epidural needle redirections during epidural placement?* Is there no difference in time to epidural loss between pre-procedural lumbar ultrasound and traditional palpation during epidural placement? Participants will be randomized to either a pre-procedural lumbar ultrasound or traditional palpation at the time of epidural placement., conditionsModule conditions: Obesity, Morbid, conditions: Labor Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Lumbar Ultrasound, outcomesModule primaryOutcomes measure: Epidural Redirects, secondaryOutcomes measure: Total time to epidural space, secondaryOutcomes measure: Number of attempts at a different level, secondaryOutcomes measure: Epidural replacement rate, secondaryOutcomes measure: Patient satisfaction, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: MetroHealth Hospital, city: Cleveland, state: Ohio, zip: 44109, country: United States, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06305234, orgStudyIdInfo id: 165-503, briefTitle: A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-20, primaryCompletionDateStruct date: 2033-11-18, completionDateStruct date: 2033-11-18, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: BioMarin Pharmaceutical, class: INDUSTRY, descriptionModule briefSummary: This is a 10-year multi-center, prospective, longitudinal, single arm study evaluating immunologic, inflammatory and laboratory parameters associated with long-term Palynziq treatment in subjects with phenylketonuria (PKU) in the United States (US). Subjects in the US for whom a clinical decision has been made that they will receive pegvaliase to treat their PKU within 30 days following the date of enrollment in Study 165-501 (incident-users) or who have previously started treatment with pegvaliase at the date of enrollment in Study 165-501 (prevalent-users) are eligible for participation in Study 165-503., conditionsModule conditions: Phenylketonuria (PKU), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Pegvaliase, outcomesModule primaryOutcomes measure: To evaluate immunologic and inflammatory responses associated with occurrences of, secondaryOutcomes measure: Evaluation of immunologic and/or inflammatory responses over time, secondaryOutcomes measure: Evaluation of immunologic responses over time, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tulane University School of Medicine, status: RECRUITING, city: New Orleans, state: Louisiana, zip: 70112, country: United States, geoPoint lat: 29.95465, lon: -90.07507, hasResults: False
protocolSection identificationModule nctId: NCT06305195, orgStudyIdInfo id: 0107766, briefTitle: Potential Correlation Between Heart Rate Variability With Cardiovascular Risk at Different Stages of Metabolic Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-08-23, primaryCompletionDateStruct date: 2024-09-01, completionDateStruct date: 2026-10-21, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Alexandria University, class: OTHER, descriptionModule briefSummary: The study aims to assess the beat-to-beat Heart rate variability (HRV) in different stages of metabolic diseases, including pre-diabetic and diabetic patients, compared to non-diabetic individuals.Heart rate variability will be compared for some antidiabetic drugs used in different stages of metabolic diseases and correlated to different metabolic and inflammatory mediators., conditionsModule conditions: Diabetes Mellitus, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 155, type: ESTIMATED, armsInterventionsModule interventions name: heart rate variability test, outcomesModule primaryOutcomes measure: Beat-to-beat Heart rate variability, primaryOutcomes measure: body mass index, primaryOutcomes measure: Valsalva ratio, primaryOutcomes measure: Stand 30:15 ratio, primaryOutcomes measure: deep breath test interpretation, secondaryOutcomes measure: Framingham risk score (FRS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Alexandria university, status: RECRUITING, city: Alexandria, country: Egypt, contacts name: Hala A. Abo El-Hassan, MSc, role: CONTACT, phone: 02/01114851485, email: hala.aboelhassan@pua.edu.eg, contacts name: Noha A. Hamdy, Dr, role: CONTACT, phone: 02/01005182151, email: noha.alaaeldine@alexu.edu.eg, geoPoint lat: 31.21564, lon: 29.95527, hasResults: False
protocolSection identificationModule nctId: NCT06305169, orgStudyIdInfo id: 1.4, briefTitle: Measuring the Negative Predictive Value and Specificity of Serum Biomarkers in Gastric Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-07-01, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Sandwell & West Birmingham Hospitals NHS Trust, class: OTHER, descriptionModule briefSummary: Atrophic gastritis where the cells of the stomach lining change is the single most important precursor condition for gastric cancer. Helicobacter pylori a bacteria which causes infection in the stomach is the most important causative agent of inflammation of the stomach, and subsequent atrophic gastritis.The difficulty with diagnosing patients with gastric cancer is that a lot of patients will suffer from heartburn and pain around the stomach, but very few of those will have gastric cancer. This makes it difficult for GPs to know who to refer for further testing as the current cancer referral criteria are very broad.To reduce the need for invasive diagnostic methods such as endoscopy where a flexible tube with camera is inserted into the gullet and stomach via the mouth, a commercially available blood test (GastroPanel ®) designed to measure the levels of certain key stomach hormones to detect atrophic gastritis has been developed. It is extremely rare for gastric cancer to develop without there first being gastric atrophy.A real word study is needed assess the performance of this blood test in a group of patients referred via an urgent cancer pathway for endoscopy in the UK. Scoring systems have been created to help us triage referrals to endoscopy in those with difficulty swallowing, but no similar score is available for those presenting with other upper abdominal symptoms. By using this blood test as well as collecting patient information we hope to create an improved referral criteria for those needing investigation for gastric cancer., conditionsModule conditions: Gastric Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 440, type: ESTIMATED, armsInterventionsModule interventions name: Gastropanel, outcomesModule primaryOutcomes measure: Measurement of the specificity and negative predictive value of serum biomarkers in gastric cancer, secondaryOutcomes measure: Creating a scoring system for patients that warrant urgent endoscopy on the cancer pathway, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Sandwell General Hospital, city: Birmingham, state: West Midlands, zip: B71 4HJ, country: United Kingdom, geoPoint lat: 52.48142, lon: -1.89983, hasResults: False
protocolSection identificationModule nctId: NCT06305156, orgStudyIdInfo id: CT_BMD_1, briefTitle: Protocol Optimization in CT for the Quantification of BMD, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-13, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-20, sponsorCollaboratorsModule leadSponsor name: Hatem Alkadhi, class: OTHER, descriptionModule briefSummary: Bone mineral density is an important measurement to detect osteoporosis.The goal of this clinical trial is to compare bone mineral density measurements in CT examinations and DXA scans. The main question it aims to answer is:* How good is the measurement of bone mineral density in the new photon-counting CT in comparison to DXA* How can we optimize the CT scan for bone mineral densityParticipants will undergo:* Clinically indicated CT scan on day of inclusion* Study related DXA scan on a separate appointment, conditionsModule conditions: Osteoporosis, Osteopenia, conditions: Bone Loss, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Bone Mineral Density quantification, outcomesModule primaryOutcomes measure: Bone mineral density CT, primaryOutcomes measure: Bone mineral density Dual-energy x-ray absorptiometry (DXA), secondaryOutcomes measure: Correlation between age and bone mineral density, secondaryOutcomes measure: Correlation between sex and bone mineral density, secondaryOutcomes measure: Correlation between height and bone mineral density, secondaryOutcomes measure: Correlation between weight and bone mineral density, secondaryOutcomes measure: Correlation between body mass index (BMI) and bone mineral density, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Diagnostic and Interventional Radiology, University Hospital Zurich, status: RECRUITING, city: Zürich, zip: 8091, country: Switzerland, contacts name: Hatem Alkadhi, MD, MPH, role: CONTACT, phone: +41 44 255 36 62, email: hatem.alkadhi@usz.ch, geoPoint lat: 47.36667, lon: 8.54999, hasResults: False
protocolSection identificationModule nctId: NCT06305143, orgStudyIdInfo id: YFZXYDK202402, briefTitle: Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-07-01, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Shanghai Eye Disease Prevention and Treatment Center, class: OTHER, collaborators name: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, descriptionModule briefSummary: The goal of this prospective multicenter open label study is to evaluate the efficacy and safety of intravitreal injection Conbercept (IVC) for the treatment of diabetic macular edema (DME) combined with severe nonproliferative diabetes retinopathy (sNPDR).The main questions it aims to answer are:* mean changes in best corrected visual acuity (BCVA) and central macular thickness (CMT) in comparison with baseline at 12 months after initial treatment* proportion of eyes with visual gain ≥15 letters in Early Treatment Diabetic Retinopathy Study (ETDRS) chart and ≥2-step improvement in Diabetic Retinopathy Severity Scale (DRSS) score after 12 months of the treatment* proportion of eyes actually underwent PRP treatment after 3 and 12 months of the treatment* mean changes in BCVA and CMT from baseline to monthly follow-up time point* complications and adverse effects, conditionsModule conditions: Diabetic Macular Edema, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 58, type: ESTIMATED, armsInterventionsModule interventions name: Conbercept, outcomesModule primaryOutcomes measure: improvement of visual acuity, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Eye Diseases Prevention &Treatment Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 201103, country: China, contacts name: Tao Sun, role: CONTACT, phone: +8618916576690, email: drsuntao@yeah.net, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06305130, orgStudyIdInfo id: KMUHIRB-E(I)-20180214, briefTitle: Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma, statusModule overallStatus: COMPLETED, startDateStruct date: 1988-01-01, primaryCompletionDateStruct date: 2023-12-31, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Kaohsiung Medical University, class: OTHER, descriptionModule briefSummary: Aim: to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma.Methods: multicentered cohort study, conditionsModule conditions: Carcinoma, Transitional Cell (RENI), designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 2515, type: ACTUAL, armsInterventionsModule interventions name: No intervention, outcomesModule primaryOutcomes measure: Overall survival, primaryOutcomes measure: Cancer-specific survival, primaryOutcomes measure: Disease-free survival, primaryOutcomes measure: Bladder recurrence-free survival, secondaryOutcomes measure: Number of patients with major postoperative complication, secondaryOutcomes measure: Number of patients with postoperative renal failure, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06305078, orgStudyIdInfo id: 2023-0528, briefTitle: Personalized Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Experiment Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-11-10, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-03-12, sponsorCollaboratorsModule leadSponsor name: Children's Hospital Medical Center, Cincinnati, class: OTHER, descriptionModule briefSummary: The primary goal of the project is to test personalized medication experiments to inform decisions about future medication use. Our central hypothesis is that our intervention will lead to within subject increases in adolescent involvement in decision making and decreases in uncertainty about future medication use. The investigators view this open label trial as a pilot study to test the feasibility, acceptability, and preliminary efficacy of the medication experiment intervention and therefore warrants further testing in a future larger trial., conditionsModule conditions: Attention Deficit Hyperactivity Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Open Label Trial, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, maskingDescription: None (open-label), enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Personalized ADHD Medication Experiment, outcomesModule primaryOutcomes measure: Decision-Making Involvement Scale, primaryOutcomes measure: Decisional Conflict Scale (DCS), primaryOutcomes measure: Behavioral Intention Questions, primaryOutcomes measure: System Usability Scale, primaryOutcomes measure: Implementation of Decision, eligibilityModule sex: ALL, minimumAge: 11 Years, maximumAge: 15 Years, stdAges: CHILD, contactsLocationsModule locations facility: Cincinnati Children's Hospital Medical Center, status: RECRUITING, city: Cincinnati, state: Ohio, zip: 45220, country: United States, contacts name: William Brinkman, MD, role: CONTACT, phone: 513-636-2576, email: bill.brinkman@cchmc.org, contacts name: William Brinkman, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 39.12713, lon: -84.51435, documentSection largeDocumentModule largeDocs typeAbbrev: Prot_SAP, hasProtocol: True, hasSap: True, hasIcf: False, label: Study Protocol and Statistical Analysis Plan, date: 2023-11-10, uploadDate: 2024-01-26T17:55, filename: Prot_SAP_000.pdf, size: 1393239, largeDocs typeAbbrev: ICF, hasProtocol: False, hasSap: False, hasIcf: True, label: Informed Consent Form, date: 2023-11-10, uploadDate: 2024-01-26T18:00, filename: ICF_001.pdf, size: 1084823, hasResults: False
protocolSection identificationModule nctId: NCT06305013, orgStudyIdInfo id: SIMU PEA 2024, briefTitle: PEA: The Ability of Nurses To Recognize It (PEA: ANTRI), acronym: PEARECOG, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-06-01, completionDateStruct date: 2024-06-01, studyFirstPostDateStruct date: 2024-03-12, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Brno University Hospital, class: OTHER, collaborators name: Department of Simulation Medicine, Faculty of Medicine, Masaryk University, descriptionModule briefSummary: The Ability to recognize cardiac arrest is crucial in emergency situations and all health care professionals should be able to do so. The identification of pulseless electrical activity can be difficult even if the theoretical knowledge of this state is well known. This research will be performed at the Simulation centre of Medical Faculty, Masaryk university and it will be focused on nurses who will come to the simulation course. All the participants will get prelearning theoretical materials that will contain chapter about pulseless electrical activity and its recognition. In the beginning of the course they will be asked to fill up the questionnaire with four different pictures of patient´s monitor in cardiac arrest. It will be evaluated whether the pulseless electrical activity will be recognized., conditionsModule conditions: Pulseless Electrical Activity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Pulseless electrical activity recognition, outcomesModule primaryOutcomes measure: Pulseless electrical activity recognition,, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 99 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Faculty hospital Brno, status: RECRUITING, city: Brno, state: Jihomoravský Kraj, zip: 62500, country: Czechia, contacts name: Martina Kosinova, MD., Ph.D., role: CONTACT, phone: 532234692, phoneExt: 00420, email: kosinova.martina@fnbrno.cz, geoPoint lat: 49.19522, lon: 16.60796, hasResults: False